Proactiveinvestors recommends
Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
EPIC: BII
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Biocompatibles
www.biocompatibles.com

Biocompatibles International plc is a leading company in the field of drug-device combination products.  The Oncology Products Division conducts the marketing of Biocompatibles’ approved oncology products.  These include products that are used for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer and prostate cancer.  Our R&D Facilities are engaged in licensing and in new product development for oncology, stroke, and diabetes and obesity.  We have collaborative agreements with AstraZeneca, Bayer Healthcare Pharmaceuticals Inc. and Medtronic Inc.

Full Biocompatibles profile here
Pdf

Biocompatibles and AstraZeneca to initiate clinical trials for anti-diabetes drug in January

7th Dec 2009, 8:58 am Biocompatibles and AstraZeneca to initiate clinical trials for anti-diabetes drug in January

Biocompatibles International (AIM: BII) and AstraZeneca (LSE: AZN) have announced that they will initiate clinical trials for their jointly developed type II anti-diabetes drug CM3 in January after the pre-clinical phase of the programme was completed ahead of schedule.


The agreement to develop the drug, which was signed by the two companies in December last year, included pre-clinical, phase I and phase IIa activities managed by Biocompatibles’ subsidiary CellMed, also providing AstraZeneca with an exclusive option to license relevant patents for further exploitation during the course of the development programme, currently slated for completion in 2012.


Phase I studies are scheduled to start in 2010, while Phase II studies will likely start later in the year.


“The first generation GLP-1s have established the drug class in treating type II diabetes but have also shown some limitations. We see CM3 as a second generation GLP-1, which has the potential to overcome these limitations. The pre-clinical results confirm that this is a realistic vision. They show that we have options for dosing and alternative routes of delivery,” said Chief Executive of Biocompatibles Crispin Simon.


AstraZeneca will pay a further €4.3 million instalment in January. The total scheduled payments make for a total of €8.8 million. Once the option to license is exercised, AstraZeneca will pay a license fee of €25 million and assume financial and management responsibility for the programme. Further milestones of €37.5 million would be payable before the product goes on sale.


Following the launch, royalties in the single to mid-teens digit range would apply, the rate depending on the level of sales achieved. In addition there is provision for sales-related milestones up to a maximum value of €256 million.
Biocompatibles said last month that its full year revenues would be closer to the upper end of the guidance after Q3 sales beat expectations. The company’s net funds are now expected to top the projected £28 million at the end of the year.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.